Syndax Pharmaceuticals (SNDX) Enterprise Value (2015 - 2026)

Syndax Pharmaceuticals' Enterprise Value history runs 12 years deep, the most recent figure standing at -$352.1 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 122.67% year-over-year to -$352.1 million in Q1 2026; TTM through Mar 2026 was -$352.1 million, a 122.67% decrease from a year earlier, with the FY2025 full-year figure at -$154.5 million, up 5.83% from the prior year.
• Enterprise Value retreated to -$352.1 million in Q1 2026 per SNDX's latest filing, from -$154.5 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$63.3 million in Q1 2023 and bottomed at -$570.7 million in Q4 2023.
• The 5-year median for Enterprise Value is -$158.1 million (2025), against an average of -$251.0 million.
• Across the five-year window, Enterprise Value jumped 84.09% in 2023 and sank 586.22% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$475.8 million in 2022, then retreated by 19.94% to -$570.7 million in 2023, then surged by 71.24% to -$164.1 million in 2024, then gained by 5.83% to -$154.5 million in 2025, then tumbled by 127.81% to -$352.1 million in 2026.
• Per Business Quant, the three latest SNDX Enterprise Value figures stand at -$352.1 million (Q1 2026), -$154.5 million (Q4 2025), and -$135.0 million (Q3 2025).